tirzepatide through lilly FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly launches Mounjaro pen in

Supply, advertising or promotion of Epitalon for human use is not permitted under the Human Medicines Regulations 2012

Our mission at TrimRx is to provide a supportive, science-driven environment where you can focus on your progress while we handle the clinical details

It activates GLP-1, GIP, and glucagon receptors to suppress appetite, improve insulin sensitivity, and increase metabolic rate

Patients may notice clothing fitting differently around the waist and face before seeing significant scale changes

Glucagon receptor engagement may augment energy expenditure and fat oxidation, potentially complementing GLP1/GIPmediated appetite and glycemic effects